METI 103
Alternative Names: METI-103Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Gachon University
- Developer MetiMedi Pharmaceuticals
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea
- 28 Sep 2024 No recent reports of development identified for preclinical development in Parkinson's-disease in South Korea
- 07 Aug 2020 METI 103 is available for licensing as of 07 Aug 2020. http://www.metimedi.com/about/collaboration.php